GlassScriptPhysician profile
Charles A Cape
NPI 1063483923
$1,909.33
in general payments reported to CMS, 2019-2025
27 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.53 · 2020: $53.98 · 2021: $151 · 2022: $232 · 2023: $459 · 2024: $630 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $248.69 | 2019-2024 | Botox |
| Vanda Pharmaceuticals INC. | $209.46 | 2020-2025 | Ponvory |
| Argenx US, INC. | $198.16 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Otsuka America Pharmaceutical, INC. | $125.19 | 2023-2024 | Nuedexta, Rexulti |
| Alnylam Pharmaceuticals INC. | $108.98 | 2022-2025 | Amvuttra, Onpattro |
| Genentech USA, INC. | $104.69 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $95.58 | 2024-2025 | |
| Lilly USA, LLC | $89.30 | 2023-2025 | Kisunla, Emgality, Amyvid |
| Eisai INC. | $88.58 | 2022-2024 | |
| Biogen, INC. | $73.10 | 2022-2024 | Skyclarys, Tysabri |
| Emd Serono, INC. | $71.59 | 2023-2024 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $67.02 | 2021 | |
| Csl Behring | $63.23 | 2020-2023 | Hizentra |
| Ucb, INC. | $62.11 | 2023-2025 | Rystiggo |
| Acorda Therapeutics, INC | $48.19 | 2023 | Inbrija |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $46.41 | 2019-2022 | |
| Lundbeck LLC | $33.46 | 2019 | |
| Amneal Pharmaceuticals LLC | $27.06 | 2019 | |
| Neurelis, INC. | $25.01 | 2025 | Valtoco |
| Tg Therapeutics, INC. | $20.54 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.08 | 2021 | |
| Avion Pharmaceuticals | $16.75 | 2022 | |
| Sobi, INC | $16.16 | 2021 | |
| Boston Scientific Corporation | $15.32 | 2022 | |
| Acadia Pharmaceuticals INC | $14.33 | 2021 | |
| Grifols USA, LLC | $11.91 | 2022 | |
| Corium, LLC | $10.43 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Cape listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.